1-[(2S)-2-[(4-amino-2,2-dioxo-1H-2lambda6,1,3-benzothiadiazin-5-yl)oxymethyl]pyrrolidin-1-yl]-2-methylpropan-1-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻二嗪
• 英文名称: 1-[(2S)-2-[(4-amino-2,2-dioxo-1H-2lambda6,1,3-benzothiadiazin-5-yl)oxymethyl]pyrrolidin-1-yl]-2-methylpropan-1-one
• 英文别名: 1-[(2S)-2-[(4-amino-2,2-dioxo-1H-2λ6,1,3-benzothiadiazin-5-yl)oxymethyl]pyrrolidin-1-yl]-2-methylpropan-1-one
• 化学式: C₁₆H₂₂N₄O₄S
• 分子量: 366.4
• InChiKey: KQGGAQSPYIUQCD-NSHDSACASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  123
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• [EN] CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES<br/>[FR] THÉRAPIES À BASE DE LIGAND DE RÉCEPTEUR CHIMIOSENSORIELS
  申请人：ELCELYX THERAPEUTICS INC

  公开号：WO2013158928A2

  公开（公告）日：2013-10-24

  Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory receptor ligand. Also provided herein are chemosensory receptor ligand compositions and methods for the preparation thereof for use in the methods of the present invention.